Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cancer interaction with the bone microenvironment: a workshop of the National Institutes of Health Tumor Microenvironment Study Section.

Literature DB >> 16651608

Cancer interaction with the bone microenvironment: a workshop of the National Institutes of Health Tumor Microenvironment Study Section.

Michael L Cher¹, Dwight A Towler, Shahin Rafii, David Rowley, Henry J Donahue, Evan Keller, Meenhard Herlyn, Eun Ah Cho, Leland W K Chung.

Abstract

Entities: Disease

Mesh：

Substances：
Peptide Hydrolases

Year: 2006 PMID： 16651608 PMCID： PMC1606588 DOI： 10.2353/ajpath.2006.050874

Source DB: PubMed Journal: Am J Pathol ISSN： 0002-9440 Impact factor: 4.307

× No keyword cloud information.

28 in total

1. RANK is essential for osteoclast and lymph node development.

Authors: W C Dougall; M Glaccum; K Charrier; K Rohrbach; K Brasel; T De Smedt; E Daro; J Smith; M E Tometsko; C R Maliszewski; A Armstrong; V Shen; S Bain; D Cosman; D Anderson; P J Morrissey; J J Peschon; J Schuh
Journal: Genes Dev Date: 1999-09-15 Impact factor: 11.361

2. Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue.

Authors: Zhong Dong; R Daniel Bonfil; Sreenivasa Chinni; Xiyun Deng; J Carlos Trindade Filho; Margarida Bernardo; Ulka Vaishampayan; Mingxin Che; Bonnie F Sloane; Shijie Sheng; Rafael Fridman; Michael L Cher
Journal: Am J Pathol Date: 2005-04 Impact factor: 4.307

3. Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model.

Authors: Jennifer A Tuxhorn; Stephanie J McAlhany; Truong D Dang; Gustavo E Ayala; David R Rowley
Journal: Cancer Res Date: 2002-06-01 Impact factor: 12.701

Review 4. Reactive stroma in prostate cancer progression.

Authors: J A Tuxhorn; G E Ayala; D R Rowley
Journal: J Urol Date: 2001-12 Impact factor: 7.450

5. Human osteocalcin and bone sialoprotein mediating osteomimicry of prostate cancer cells: role of cAMP-dependent protein kinase A signaling pathway.

Authors: Wen-Chin Huang; Zhihui Xie; Hiroyuki Konaka; Jaro Sodek; Haiyen E Zhau; Leland W K Chung
Journal: Cancer Res Date: 2005-03-15 Impact factor: 12.701

Review 6. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment.

Authors: K S Koeneman; F Yeung; L W Chung
Journal: Prostate Date: 1999-06-01 Impact factor: 4.104

7. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis.

Authors: Jeffrey A Nemeth; Rafid Yousif; Michael Herzog; Mingxin Che; Jyoti Upadhyay; Bijan Shekarriz; Sunita Bhagat; Chadwick Mullins; Rafael Fridman; Michael L Cher
Journal: J Natl Cancer Inst Date: 2002-01-02 Impact factor: 13.506

8. Breast cancer metastatic potential correlates with a breakdown in homospecific and heterospecific gap junctional intercellular communication.

Authors: M M Saunders; M J Seraj; Z Li; Z Zhou; C R Winter; D R Welch; H J Donahue
Journal: Cancer Res Date: 2001-03-01 Impact factor: 12.701

9. Synthetic matrix metalloproteinase inhibitors inhibit growth of established breast cancer osteolytic lesions and prolong survival in mice.

Authors: Bent Winding; Róisín NicAmhlaoibh; Henriette Misander; Pernille Høegh-Andersen; Thomas Levin Andersen; Claus Holst-Hansen; Anne-Marie Heegaard; Niels Taekker Foged; Nils Brünner; Jean-Marie Delaissé
Journal: Clin Cancer Res Date: 2002-06 Impact factor: 12.531

10. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand.

Authors: Beate Heissig; Koichi Hattori; Sergio Dias; Matthias Friedrich; Barbara Ferris; Neil R Hackett; Ronald G Crystal; Peter Besmer; David Lyden; Malcolm A S Moore; Zena Werb; Shahin Rafii
Journal: Cell Date: 2002-05-31 Impact factor: 41.582

11 in total

1. 188Re-labelled gemcitabine/bisphosphonate (Gem/BP): a multi-functional, bone-specific agent as a potential treatment for bone metastases.

Authors: Amal A El-Mabhouh; John R Mercer
Journal: Eur J Nucl Med Mol Imaging Date: 2008-02-12 Impact factor: 9.236

2. Synthesis, spectral characterization, and in vitro cellular activities of metapristone, a potential cancer metastatic chemopreventive agent derived from mifepristone (RU486).

Authors: Jichuang Wang; Jianzhong Chen; Liyuan Wan; Jingwei Shao; Yusheng Lu; Yewei Zhu; Minrui Ou; Suhong Yu; Haijun Chen; Lee Jia
Journal: AAPS J Date: 2014-01-18 Impact factor: 4.009

Review 3. Novel therapies for metastatic castrate-resistant prostate cancer.

Authors: Farshid Dayyani; Gary E Gallick; Christopher J Logothetis; Paul G Corn
Journal: J Natl Cancer Inst Date: 2011-09-13 Impact factor: 13.506

4. COX-2 and prostaglandin EP3/EP4 signaling regulate the tumor stromal proangiogenic microenvironment via CXCL12-CXCR4 chemokine systems.

Authors: Hiroshi Katoh; Kanako Hosono; Yoshiya Ito; Tatsunori Suzuki; Yasufumi Ogawa; Hidefumi Kubo; Hiroki Kamata; Toshiaki Mishima; Hideaki Tamaki; Hiroyuki Sakagami; Yukihiko Sugimoto; Shuh Narumiya; Masahiko Watanabe; Masataka Majima
Journal: Am J Pathol Date: 2010-01-28 Impact factor: 4.307

9. Perlecan/HSPG2 and matrilysin/MMP-7 as indices of tissue invasion: tissue localization and circulating perlecan fragments in a cohort of 288 radical prostatectomy patients.

Authors: Brian Grindel; Quanlin Li; Rebecca Arnold; John Petros; Majd Zayzafoon; Mark Muldoon; James Stave; Leland W K Chung; Mary C Farach-Carson
Journal: Oncotarget Date: 2016-03-01

Review 10. Current Controversies on the Pathogenesis of Medication-Related Osteonecrosis of the Jaw.

Authors: Winnie Zee Man Wat
Journal: Dent J (Basel) Date: 2016-10-28